+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

RNA-based Therapeutics and Vaccines - Global Market Trajectory & Analytics

  • ID: 5309813
  • Report
  • April 2021
  • Region: Global
  • 147 pages
  • Global Industry Analysts, Inc
Global RNA-based Therapeutics and Vaccines Market to Reach $499 Million by 2027

Amid the COVID-19 crisis, the global market for RNA-based Therapeutics and Vaccines estimated at US$14.7 Million in the year 2020, is projected to reach a revised size of US$499 Million by 2027, growing at a CAGR of 65.5% over the period 2020-2027. RNA-based Therapeutics, one of the segments analyzed in the report, is projected to record 68.1% CAGR and reach US$372.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA-based Vaccines segment is readjusted to a revised 59.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $4.5 Million, While China is Forecast to Grow at 62% CAGR

The RNA-based Therapeutics and Vaccines market in the U.S. is estimated at US$4.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$76.6 Million by the year 2027 trailing a CAGR of 62% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 59.2% and 55.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 43.7% CAGR.

Select Competitors (Total 41 Featured):
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • BioNTech AG
  • CureVac AG
  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics, Inc.
  • Moderna, Inc.
  • Quark Pharmaceuticals, Inc.
  • Regulus Therapeutics, Inc.
  • Sylentis S.A.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for RNA-based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for RNA-based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for RNA-based Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for RNA-based Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Genetic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Genetic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 21: USA Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 22: USA 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 23: USA Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 24: USA 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • CANADA
  • Table 25: Canada Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 27: Canada Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 28: Canada 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • JAPAN
  • Table 29: Japan Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 30: Japan 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 31: Japan Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • CHINA
  • Table 33: China Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 34: China 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 35: China Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 36: China 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • EUROPE
  • Table 37: Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
  • Table 38: Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 39: Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 40: Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 41: Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 42: Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • FRANCE
  • Table 43: France Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 44: France 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 45: France Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 46: France 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • GERMANY
  • Table 47: Germany Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 48: Germany 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 49: Germany Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 50: Germany 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • ITALY
  • Table 51: Italy Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 52: Italy 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 53: Italy Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 54: Italy 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • UNITED KINGDOM
  • Table 55: UK Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 56: UK 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 57: UK Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 58: UK 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • REST OF EUROPE
  • Table 59: Rest of Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 60: Rest of Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 61: Rest of Europe Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 62: Rest of Europe 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • ASIA-PACIFIC
  • Table 63: Asia-Pacific Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 64: Asia-Pacific 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 65: Asia-Pacific Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 66: Asia-Pacific 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
  • REST OF WORLD
  • Table 67: Rest of World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Product Type - RNA-based Therapeutics and RNA-based Vaccines - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 68: Rest of World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Product Type - Percentage Breakdown of Value Sales for RNA-based Therapeutics and RNA-based Vaccines for the Years 2020 & 2027
  • Table 69: Rest of World Current & Future Analysis for RNA-based Therapeutics and Vaccines by Indication - Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
  • Table 70: Rest of World 7-Year Perspective for RNA-based Therapeutics and Vaccines by Indication - Percentage Breakdown of Value Sales for Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases and Other Indications for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll